Cargando…

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction

OBJECTIVE: The purpose of this study was to evaluate the feasibility and safety in terms of prognostic significance and perioperative morbidity and mortality of cytoreduction in patients affected by advance ovarian cancer and hepato-biliary metastasis. METHODS: Patients with a least one hepatobiliar...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Donato, Violante, Giannini, Andrea, D’Oria, Ottavia, Schiavi, Michele Carlo, Di Pinto, Anna, Fischetti, Margherita, Lecce, Francesca, Perniola, Giorgia, Battaglia, Francesco, Berloco, Pasquale, Muzii, Ludovico, Benedetti Panici, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752869/
https://www.ncbi.nlm.nih.gov/pubmed/32779050
http://dx.doi.org/10.1245/s10434-020-08989-3
_version_ 1783625951113904128
author Di Donato, Violante
Giannini, Andrea
D’Oria, Ottavia
Schiavi, Michele Carlo
Di Pinto, Anna
Fischetti, Margherita
Lecce, Francesca
Perniola, Giorgia
Battaglia, Francesco
Berloco, Pasquale
Muzii, Ludovico
Benedetti Panici, Pierluigi
author_facet Di Donato, Violante
Giannini, Andrea
D’Oria, Ottavia
Schiavi, Michele Carlo
Di Pinto, Anna
Fischetti, Margherita
Lecce, Francesca
Perniola, Giorgia
Battaglia, Francesco
Berloco, Pasquale
Muzii, Ludovico
Benedetti Panici, Pierluigi
author_sort Di Donato, Violante
collection PubMed
description OBJECTIVE: The purpose of this study was to evaluate the feasibility and safety in terms of prognostic significance and perioperative morbidity and mortality of cytoreduction in patients affected by advance ovarian cancer and hepato-biliary metastasis. METHODS: Patients with a least one hepatobiliary metastasis who have undergone surgical treatment with curative intent of were considered for the study. Perioperative complications were evaluated and graded with Accordion severity Classification. Five-year PFS and OS were estimated using the Kaplan–Meier curve. RESULTS: Sixty-seven (20.9%) patients had at least one metastasis to the liver, biliary tract, or porta hepatis. Forty-four (65.7%) and 23 (34.3%) patients underwent respectively high and intermediate complexity surgery according. Complete cytoreduction was achieved in 48 (71.6%) patients with hepato-biliary disease. In two patients (2.9%) severe complications related to hepatobiliary surgery were reported. The median PFS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) was 19 months [95% confidence interval (CI) 16.2–21.8] and 8 months (95% CI 6.1–9.9). The median OS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) 45 months (95% CI 21.2–68.8 months) and 23 months (95% CI 13.9–32.03). CONCLUSIONS: Hepatobiliary involvement is often associated with high tumor load and could require high complex multivisceral surgery. In selected patients complete cytoreduction could offer survival benefits. Morbidity related to hepatobiliary procedures is acceptable. Careful evaluation of patients and multidisciplinary approach in referral centers is mandatory. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-08989-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7752869
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77528692020-12-28 Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction Di Donato, Violante Giannini, Andrea D’Oria, Ottavia Schiavi, Michele Carlo Di Pinto, Anna Fischetti, Margherita Lecce, Francesca Perniola, Giorgia Battaglia, Francesco Berloco, Pasquale Muzii, Ludovico Benedetti Panici, Pierluigi Ann Surg Oncol Peritoneal Surface Malignancy OBJECTIVE: The purpose of this study was to evaluate the feasibility and safety in terms of prognostic significance and perioperative morbidity and mortality of cytoreduction in patients affected by advance ovarian cancer and hepato-biliary metastasis. METHODS: Patients with a least one hepatobiliary metastasis who have undergone surgical treatment with curative intent of were considered for the study. Perioperative complications were evaluated and graded with Accordion severity Classification. Five-year PFS and OS were estimated using the Kaplan–Meier curve. RESULTS: Sixty-seven (20.9%) patients had at least one metastasis to the liver, biliary tract, or porta hepatis. Forty-four (65.7%) and 23 (34.3%) patients underwent respectively high and intermediate complexity surgery according. Complete cytoreduction was achieved in 48 (71.6%) patients with hepato-biliary disease. In two patients (2.9%) severe complications related to hepatobiliary surgery were reported. The median PFS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) was 19 months [95% confidence interval (CI) 16.2–21.8] and 8 months (95% CI 6.1–9.9). The median OS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) 45 months (95% CI 21.2–68.8 months) and 23 months (95% CI 13.9–32.03). CONCLUSIONS: Hepatobiliary involvement is often associated with high tumor load and could require high complex multivisceral surgery. In selected patients complete cytoreduction could offer survival benefits. Morbidity related to hepatobiliary procedures is acceptable. Careful evaluation of patients and multidisciplinary approach in referral centers is mandatory. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-020-08989-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-08-10 2021 /pmc/articles/PMC7752869/ /pubmed/32779050 http://dx.doi.org/10.1245/s10434-020-08989-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Peritoneal Surface Malignancy
Di Donato, Violante
Giannini, Andrea
D’Oria, Ottavia
Schiavi, Michele Carlo
Di Pinto, Anna
Fischetti, Margherita
Lecce, Francesca
Perniola, Giorgia
Battaglia, Francesco
Berloco, Pasquale
Muzii, Ludovico
Benedetti Panici, Pierluigi
Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
title Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
title_full Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
title_fullStr Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
title_full_unstemmed Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
title_short Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
title_sort hepatobiliary disease resection in patients with advanced epithelial ovarian cancer: prognostic role and optimal cytoreduction
topic Peritoneal Surface Malignancy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752869/
https://www.ncbi.nlm.nih.gov/pubmed/32779050
http://dx.doi.org/10.1245/s10434-020-08989-3
work_keys_str_mv AT didonatoviolante hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT gianniniandrea hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT doriaottavia hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT schiavimichelecarlo hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT dipintoanna hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT fischettimargherita hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT leccefrancesca hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT perniolagiorgia hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT battagliafrancesco hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT berlocopasquale hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT muziiludovico hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction
AT benedettipanicipierluigi hepatobiliarydiseaseresectioninpatientswithadvancedepithelialovariancancerprognosticroleandoptimalcytoreduction